Loading...
Loading...
JAGX| Name | Value |
|---|---|
| Revenues | 2,300.0K |
| Cost of Revenue | 1,278.0K |
| Gross Profit | 1,022.0K |
| Operating Expense | 8,208.0K |
| Operating I/L | -7,186.0K |
| Other Income/Expense | -2,123.0K |
| Interest Income | -6,134.0K |
| Pretax | -9,309.0K |
| Income Tax Expense | -139.0K |
| Net Income/Loss | -9,170.0K |
Jaguar Health, Inc. is a pharmaceutical company specializing in prescription medicines for gastrointestinal distress in humans and animals. Its flagship product, Mytesi, targets noninfectious diarrhea in adults with HIV/AIDS. The company also develops Crofelemer for various indications, including cancer therapy-related diarrhea and inflammatory bowel diseases. Additionally, it is working on lechlemer for cholera and Canalevia for chemotherapy-induced and exercise-induced diarrhea in dogs. With a focus on chronic and debilitating diarrhea, Jaguar Health, Inc. operates through segments for Human Health and Animal Health, generating revenue from the sale of its prescription medicines and drug candidates.
